Pilot Research on Opioid Use Disorder (PROUD)
Pilot Evaluation of the Empower Neuromodulation System in OUD Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94121
- Northern California Institute for Research and Education
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- VA-eligible Veterans
- Ages ≥ 18
- Current diagnosis of opioid use disorder per DSM-5 by clinician assessment
- Scheduled to initiate, or has initiated within the past five days, treatment for OUD with buprenorphine/naloxone
Exclusion Criteria:
- Injury or nerve damage at the arm or palm and/or neuropathy in the upper extremities
- Pregnant or planning to become pregnant
- Currently implanted with an electrical and/or neurostimulator device (e.g. pacemaker, defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, sacral stimulator, bone growth stimulator, or cochlear implant)
- Use of an investigational drug/device therapy within the past 4 weeks
- History of epilepsy or a seizure disorder
- Has an electrically conductive metal object (e.g. jewelry) that cannot be removed and will directly contact the gel electrodes of the Empower Neuromodulation System when applied to the skin at the stimulation location
- Unable to provide informed written consent
- Has taken a medication-assisted treatment (MAT) for OUD in the past two weeks or plans to take any prescription opioid or MAT for OUD other than buprenorphine/naloxone while enrolled in the study
- Is deemed unsuitable for enrollment in the study by the PI (e.g. current medical or psychiatric instability)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Active treatment
Participants will self-administer treatment with the Empower device at the active treatment anatomic location once daily for three weeks.
Participants will complete daily and weekly surveys to evaluate the effects of the Empower active treatment.
|
Peripheral nerve stimulation with the Empower device.
The active and sham treatments only differ by the location of application on the body.
|
|
Sham Comparator: Sham treatment
Participants will self-administer treatment with the Empower device at the sham treatment anatomic location once daily for three weeks.
Participants will complete daily and weekly surveys to evaluate the effects of the Empower sham treatment.
|
Peripheral nerve stimulation with the Empower device.
The active and sham treatments only differ by the location of application on the body.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Opioid craving intensity
Time Frame: 3 weeks
|
Self-reported opioid craving intensity via daily 100-mm visual-analog scale (VAS).
The VAS has a minimum score of 0 (no craving) and a maximum score of 100 (severe craving).
|
3 weeks
|
|
Adverse events
Time Frame: 3 weeks
|
Safety assessment via device-related adverse events.
|
3 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Opioid use
Time Frame: 3 weeks
|
Number of positive outcomes in urine screening tests for opioids.
|
3 weeks
|
|
Clinical opioid withdrawal scale (COWS). The COWS is an 11-item, clinician-administered tool that measures a patient's withdrawal symptoms. The COWS has a minimum score of 0 (no withdrawal) and a maximum score of 48 (severe withdrawal).
Time Frame: Week one of the 3-week study
|
Change in COWS score.
|
Week one of the 3-week study
|
|
Subjective opioid withdrawal scale (SOWS). The SOWS is an 16-item, self-reported questionnaire that measures a patient's withdrawal symptoms. The SOWS has a minimum score of 0 (no withdrawal) and a maximum score of 64 (severe withdrawal).
Time Frame: Week one of the 3-week study
|
Change in SOWS score.
|
Week one of the 3-week study
|
|
System usability scale (SUS)
Time Frame: 3 weeks
|
Self-reported assessment of system usability.
The SUS is a 10-item, self-reported questionnaire that measures usability of the system.
The SUS has a minimum score of 0 (extremely poor usability) and a maximum score of 100 (excellent usability).
|
3 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Michael Vice President, TheraNova, LLC
- Principal Investigator: Ellen Principal Investigator, Northern California Institute of Research and Education
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CRD-12-1209-01
- R43DA049623 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.